Interleukin Inhibitors Market Size To Reach $72.2 Billion By 2030

Interleukin Inhibitors Market Growth & Trends

The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

 Request a free sample copy or view report summary: Interleukin Inhibitors Market Report

Interleukin Inhibitors Market Report Highlights

• By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024

• In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.

• By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.

• Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.

• Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Interleukin Inhibitors Market Segmentation

Grand View Research has segmented the global interleukin inhibitors market based on type, route of administration, application, end-use, and region:

Interleukin Inhibitor Type Outlook (Revenue, USD Million, 2018 - 2030)

• IL-1 Inhibitors

• IL-2 Inhibitors

• IL-5 Inhibitors

• IL-6 Inhibitors

• IL-17 Inhibitors

• IL-23 Inhibitors

• Others

Interleukin Inhibitor Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Subcutaneous (SC)

• Intravenous (IV)

Interleukin Inhibitor Application Outlook (Revenue, USD Million, 2018 - 2030)

• Rheumatoid Arthritis

• Psoriasis

• Inflammatory Bowel Disease (IBD)

• Asthma

• Others

Interleukin Inhibitor End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Others

Interleukin Inhibitor Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Interleukin Inhibitors Market

• Novartis AG

• AbbVie Inc.

• Eli Lilly and Company

• Regeneron Pharmaceuticals Inc.

• Johnson & Johnson Services, Inc.

• F. Hoffmann-La Roche Ltd

• AstraZeneca

• Bausch Health Companies Inc.

• GlaxoSmithKline plc

• Teva Pharmaceutical Industries Ltd